Seven Fleet Capital Management LP Takes $3.05 Million Position in Compass Therapeutics, Inc. $CMPX

Posted by George Bondi on Jun 19th, 2026

Seven Fleet Capital Management LP purchased a new stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 568,747 shares of the company’s stock, valued at approximately $3,054,000. Compass Therapeutics makes up about 2.3% of Seven Fleet Capital Management LP’s portfolio, making the stock its 5th largest holding. Seven Fleet Capital Management LP owned approximately 0.32% of Compass Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Russell Investments Group Ltd. increased its position in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the last quarter. Creative Planning purchased a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $30,000. Flagship Harbor Advisors LLC purchased a new position in shares of Compass Therapeutics during the 4th quarter valued at about $32,000. Strs Ohio bought a new position in shares of Compass Therapeutics in the first quarter worth approximately $34,000. Finally, CIBC Bancorp USA Inc. bought a new position in Compass Therapeutics in the 3rd quarter worth $37,000. 68.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on CMPX shares. Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a report on Monday, June 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research note on Thursday, March 12th. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. William Blair restated an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $12.91.

Check Out Our Latest Analysis on Compass Therapeutics

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $2.02 on Friday. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88. The company has a 50-day simple moving average of $2.90 and a two-hundred day simple moving average of $4.66. The company has a market capitalization of $363.78 million, a PE ratio of -4.93 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). On average, equities analysts predict that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

(Free Report)

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.